Canadian Cancer Trials Group Bulletins


Canadian Cancer Trials Group Receives CIHR Funding

We are extremely pleased to announce that the Canadian Cancer Trials Group has received funding from the Canadian Institutes of Health Research (CIHR) totalling almost $4M to support two Canadian Cancer Trials Group international trials -- CX.5 and GA.1.

Canadian Cancer Trials Group CX.5 -- A Randomized Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer -- will be led by the Canadian Cancer Trials Group and will include participation from a number of international groups who are part of the Gynecologic Cancer Intergroup. The Principal Investigator of the trial is Dr. Marie Plante, and co-investigators include Tony Fyles, Peter Craighead, Gavin Stuart, Dongsheng Tu, Michael Brundage, Lori Brotto, Janice Kwon, Nicole Mittmann, Sarah Ferguson, Jocelyne Arseneau, Mostafa Atri, and Ralph Meyer.

This trial received $2.2M over 8 years from CIHR. The objective of this trial is to compare the outcome and quality of life between standard radical hysterectomy and nodes versus simple hysterectomy and nodes in low-risk disease. This work has the potential to be a groundbreaking and practice-changing study. The total number of patients will be 700.

Canadian Cancer Trials Group GA.1 -- A Randomized Phase III Trial of Preoperative Chemoradiotherapy vs Preoperative Chemotherapy for Resectable Gastric Cancer -- will be conducted collaboratively with the Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG), which are both based in Australia, and the European Organization for Research and Treatment of Cancer (EORTC). Dr. Rebecca Wong is the Principal Investigator, and co-investigators include Christian Kollmansberger, Derek Jonker, Dongsheng Tu, Jolie Ringash, Nicole Mittmann, Carol Swallow, Gail Darling, Geoffrey Liu, and Chris O'Callaghan.

GA.1 received $1.7M over 7 years from CIHR. This trial will assess whether adding preoperative chemoradiation therapy to a standard therapy improves survival in comparison with standard therapy alone in patients with resectable gastric or gastroesophageal junction cancer. To assess overall survival, 752 patients will be recruited.

We look forward to successfully activating these trials in the next few months.

Congratulations to all!!